Tumor-targeting *Salmonella typhimurium* A1-R inhibits human prostate cancer experimental bone metastasis in mouse models

Makoto Toneri¹,²,³, Shinji Miwa¹,², Yong Zhang¹, Cameron Hu¹, Shuya Yano¹,², Yasunori Matsumoto², Michael Bouvet², Hayao Nakanishi⁴, Robert M. Hoffman¹,² and Ming Zhao¹

¹ AntiCancer, Inc., San Diego, California, USA
² Department of Surgery, University of California, San Diego, California, USA
³ Ageo Medical Group, Saitama, Japan
⁴ Laboratory of Pathology and Clinical Research, Aichi Cancer Center Aichi Hospital, Aichi, Japan

Correspondence to: Ming Zhao, email: all@anticancer.com
Robert M. Hoffman, email: all@anticancer.com

Keywords: prostate cancer, bone metastasis, GFP/RFP, zoledronic acid, bacterial therapy

Received: July 20, 2015  Accepted: August 14, 2015  Published: September 28, 2015

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting *Salmonella typhimurium* A1-R were analyzed in vitro and in vivo on prostate cancer cells and experimental bone metastasis. Both ZOL and *S. typhimurium* A1-R inhibited the growth of PC-3 cells expressing red fluorescent protein in vitro. To investigate the efficacy of *S. typhimurium* A1-R on prostate cancer experimental bone metastasis, we established models of both early and advanced stage bone metastasis. The mice were treated with ZOL, *S. typhimurium* A1-R, and combination therapy of both ZOL and *S. typhimurium* A1-R. ZOL and *S. typhimurium* A1-R inhibited the growth of solitary bone metastases. *S. typhimurium* A1-R treatment significantly decreased bone metastasis and delayed the appearance of PC-3 bone metastases of multiple mouse models. Additionally, *S. typhimurium* A1-R treatment significantly improved the overall survival of the mice with multiple bone metastases. The results of the present study indicate that *S. typhimurium* A1-R is useful to prevent and inhibit prostate cancer bone metastasis and has potential for future clinical use in the adjuvant setting.

INTRODUCTION

Prostate cancer is diagnosed in more than 500,000 men worldwide [1]. Bone metastases from prostate cancer can cause chronic pain, hypercalcemia, pathologic fractures, and nerve compression [2]. Zoledronic acid (ZOL), a bisphosphonate, has been used to prevent the development of metastatic bone lesions. Although bisphosphonates, irradiation, and surgical resection of tumors are used as treatments of bone metastases, the outcomes of the treatments are still unsatisfactory.

*S. typhimurium* (S. typhimurium) A1-R, is a genetically-engineered strain of *Salmonella* that is able to specifically target cancer cells [3]. S. typhimurium A1-R was able to inhibit or eradicate primary and metastatic tumors as monotherapy in nude mouse models of prostate [3, 4], breast [5-7], lung [8, 9], pancreatic [10-14], ovarian [15, 16], stomach [17] and cervical cancer [18], as well as sarcoma [19-23] and glioma [24, 25], all of which are highly aggressive tumor models. Tumors with a high degree of vascularity were more sensitive to *S. typhimurium* A1-R, and vascular destruction appears to
play a role in *S. typhimurium* A1-R antitumor efficacy [25]. Tumor vessel destruction and tumor-growth inhibition were enhanced by primer dosing of *S. typhimurium* A1-R in immunocompetent transgenic mice expressing the nestin-driven green fluorescent protein (ND-GFP), which is selectively expressed in nascent blood vessels [26].

In the present study, the efficacy of *S. typhimurium* A1-R and the combination of *S. typhimurium* A1-R and ZOL was assessed in nude mice models of solitary and multiple bone metastases of prostate cancer.

**RESULTS AND DISCUSSION**

**Efficacy of *S. typhimurium* A1-R on human prostate cancer cells in vitro**

To determine the efficacy of A1-R on prostate cancer cells, PC-3-RFP cells were incubated in 35 mm dishes for 24 h, and the cells were treated with *S. typhimurium* A1-R for 1 h. The cells were observed with a Fluoview FV1000 confocal microscope (Olympus Corp., Tokyo, Japan). Fluorescence imaging demonstrated that *S. typhimurium* A1-R expressing GFP selectively invaded and replicated intracellularly and killed PC-3-RFP cells (Figure 1). Clonogenic assays demonstrated that *S. typhimurium* A1-R inhibited proliferation of PC-3-RFP cells in a dose-dependent manner (Figure 2).

**Efficacy of *S. typhimurium* A1-R therapy on a mouse model of multiple bone metastasis**

Nude mice were injected in the left ventricle with PC-3-GFP cells (5 × 10⁵). One week after intracardiac injection, half of the mice were treated once a week for 3 weeks with an i.v. injection of *S. typhimurium* A1-R (5 × 10⁷ CFU) (Figure 3a). Time-course fluorescence imaging of the study mice revealed GFP-expressing tumor growth in the control group and little tumor growth in the *S. typhimurium* A1-R group (Figure 3b). *S. typhimurium* A1-R significantly improved the metastasis-free survival and overall survival of the mice (Figure 3c, 3d).

**Figure 1: Efficacy of *S. typhimurium* A1-R in vitro on prostate cancer cells.** PC-3-RFP cells were incubated in 35 mm dishes for 24 h. The cells were treated with *S. typhimurium* A1-R for 1 h. The PC-3-RFP cells were rinsed with PBS and the cells were observed with the FV1000 confocal microscope. Fluorescence images were obtained at 24 hours after infection and demonstrated that *S. typhimurium* A1-R expressing GFP invaded a, and replicated intracellularly b, in PC-3-RFP cells. After the invasion and replication of GFP-expressing *S. typhimurium* A1-R, the infected cells shrunk c, and fragmented d. See Materials and Methods for details.
Efficacy of *S. typhimurium* A1-R on a mouse model of solitary bone metastasis of prostate cancer

PC-3-RFP (5 × 10^5) cells were injected into the intramedullary cavity of the tibia in nude mice (Figure 4a). One week after the injection, the mice were divided into 4 groups: a control group, a ZOL group, an A1-R group, and a ZOL+ *S. typhimurium* A1-R group. ZOL-group mice were treated with subcutaneous injection of ZOL (120 mg/kg) (Sigma-Aldrich. St. Louis, MO) 5 times a week for 4 weeks (Figure 4b). *S. typhimurium* A1-R group mice were treated with weekly i.v. injections of *S. typhimurium* A1-R (5 × 10^7 CFU) for a total of 3 weeks. ZOL+ *S. typhimurium* A1-R-group mice were treated with both s.c. injection of ZOL and i.v. injection of *S. typhimurium* A1-R at the same dosages listed above. Fluorescence imaging was performed with an iBOX Scientia Imaging System (UVP, LLC, Upland, CA) every week. The fluorescence images demonstrated that the control group had rapid growth of metastatic bone cancer, whereas the ZOL group, *S. typhimurium* A1-R group, and the ZOL+ *S. typhimurium* A1-R group mice had reduced metastatic growth (Figure 4c). The fluorescent tumor area of the control-group mice was 54.9 ± 6.1 mm^2, ZOL group at 4 weeks mice was 29.1 ± 9.2 mm^2, *S. typhimurium* A1-R-group mice was 23.8 ± 6.1 mm^2, and ZOL+ *S. typhimurium* A1-R group mice was 18.4 ± 5.3 mm^2 (Figure 4d). The *S. typhimurium* A1-R group and the ZOL+ *S. typhimurium* A1-R group had significant inhibition of tumor growth compared to the control group. Four weeks after the injection of cancer cells, the mice were sacrificed and tumor weight was measured. Tumor weights of the control group was 2.6 ± 0.6 g; ZOL group was 0.5 ± 0.2 g; *S. typhimurium* A1-R group was 1.1 ± 0.6; and ZOL+ *S. typhimurium* A1-R group mice at 4 weeks was 0.3 ± 0.1 g (Figure 4e).

The tumor targeting of prostate cancer-bone metastasis strategy, developed in the present report, could also be used with previously-developed tumor targeting strategies [27-34].

The present study demonstrates that *S. typhimurium* A1-R could significantly inhibit or prevent prostate cancer metastasis in the bone. These results indicate a promising approach to a currently highly treatment-resistant disease.

**Figure 2:** Growth inhibitory effect of A1-R *in vitro*. Clonogenic assays were performed as previously described [40]. PC-3-RFP cells 1 × 10^5 were incubated in 35 mm dishes. PC-3-RFP colonies were fixed with methanol and stained with 1% crystal violet 8 days after zoledronic acid (ZOL) or *S. typhimurium* A1-R (1 × 10^7 or 1 × 10^8 CFU/dish). PC-3-RFP cells were plated in 35 mm dishes. ImageJ (National Institutes of Health, Bethesda, Maryland, USA) was used to quantify the areas of the colonies of the cells. **a.** Colonies after treatment with ZOL or *S. typhimurium* A1-R. **b.** PC-3-RFP colony area decreased after treatment with ZOL or *S. typhimurium* A1-R. ZOL inhibited the growth of PC-3-RFP cells compared to the untreated control group. *S. typhimurium* A1-R also inhibited the growth of PC-3-RFP cells in a dose-dependent manner (*p < 0.05, **p < 0.01).
Figure 3: Efficacy of *S. typhimurium* A1-R on multiple bone metastasis. 

**a.** PC-3-GFP cells were injected into the left ventricle in nude mice. On day 7, 14, and 21, *S. typhimurium* A1-R (5×10⁷ CFU/mouse) was administered i.v. Fluorescence imaging was performed every week. Metastasis-free survival and overall survival of mice treated with *S. typhimurium* A1-R or untreated controls was determined using the Kaplan-Meier method with the log-rank test. 

**b.** Time-course fluorescence imaging of prostate cancer bone metastasis with or without treatment of *S. typhimurium* A1-R. PC-3-GFP cells were inoculated into the left cardiac ventricle of nude mice. Fluorescence imaging visualized the progression of metastases in control mice. In contrast, there was only a small increase in fluorescence in the mice treated with *S. typhimurium* A1-R. 

**c.** Metastasis-free survival. 

**d.** Overall survival.
MATERIALS AND METHODS

Cell culture

PC-3 cells, which were originally established from metastatic bone lesions of human prostate cancer [35], were labeled with GFP or RFP. PC-3-RFP and PC-3-GFP cells were generated as previously described [36-39]. Cells were maintained in RPMI 1640 with 10% FBS + 1% penicillin streptomycin solution. Cells were subcultured for at least 3 passages before harvesting at their linear growth phase (approximately 70-80% confluent) for intracardiac or intramedullary injection at 5 × 10^5 cells/mouse.

Animal care

Athymic nude mice (nu/nu) (AntiCancer Inc, San Diego, CA) were used in this study. Mice were maintained in a barrier facility of high efficiency particulate air-filtered racks. The animals were fed an autoclaved laboratory rodent diet. Animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals under National Institutes of Health assurance number A3873-01.

Preparation of S. typhimurium A1-R

GFP-expressing S. typhimurium A1-R bacteria (AntiCancer Inc., San Diego, CA, USA) were grown overnight on LB medium (Fisher Sci., Hanover Park, IL, USA).
USA) and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS [3, 5].

S. typhimurium A1-R killing of prostate cancer cells in vitro

PC-3-RFP cells were plated in 35 mm dishes (5 × 10^5 cells/dish). S. typhimurium A1-R-GFP was added to the cancer cells (1 × 10^7 or 1 × 10^8 CFU/dish). After 1 h incubation at 37°C, the cells were rinsed and cultured in medium containing gentamycin sulfate (100 µg/ml) to kill external but not internal bacteria. Invasion and destruction of PC-3-RFP cells by S. typhimurium A1-R-GFP was visualized with a Fluoview FV1000 confocal microscope (Olympus Corp., Tokyo, Japan). Eight days after treatment with S. typhimurium A1-R, PC-3-RFP colonies were fixed in methanol and stained with 1% crystal violet as previously described [40]. ImageJ (National Institute of Mental Health, Bethesda, Maryland, USA) was used to quantify the area of the colonies of the cells.

Efficacy of S. typhimurium A1-R therapy on a mouse model of multiple bone metastases

PC-3-GFP cells (5 × 10^5) were injected intracardially in nude mice. One week after injection, mice (treatment group) were administered S. typhimurium A1-R (5 × 10^7 CFU, i.v.) once a week for 3 weeks. The remaining mice (control group) were administered the same volume of PBS. To evaluate metastasis-free survival, GFP-expressing lesions were initially observed using the Illumatool imaging system (Lighttools Research, Encinitas, CA) every 2 days. Metastasis-free survival was defined as the time from intracardiac injection of cancer cells to the time of detection of bone metastases with the Illumatool.

Efficacy of S. typhimurium therapy on a mouse model of solitary bone metastases

A midline skin incision (5 mm) was made just below the knee joint to expose the tibial tuberosity (Figure 4a). Matrigel (5 µL) (BD Bioscience, San Jose, CA) and PC-3-RFP cells (5 × 10^5) were co-injected into the intramedullary cavity of the tibia with a 1.0 mL 28 G latex-free insulin syringe (BD and Company, Franklin Lakes, NJ). The skin was closed with a 6-0 suture. One week after injection, fluorescence imaging was performed to confirm the RFP-expressing tumor was growing, using the iBOX Scientia (UVP LLC, Upland, CA). The study mice were randomly divided into the following groups: control group; ZOL group; S. typhimurium A1-R group; and ZOL+ S. typhimurium A1-R group. In the ZOL group, mice were treated with subcutaneous injection of 120 mg/kg ZOL for 5 times a week for 4 weeks (Figure 4b). S. typhimurium A1-R-group mice were administered S. typhimurium A1-R (5 × 10^7 CFU, i.v.) once a week for 3 weeks. ZOL+ S. typhimurium A1-R-group mice were administered both treatments. Fluorescence imaging was performed on treated and untreated mice, and GFP-expressing areas were recorded every week for 5 weeks using the iBOX. At the end of the follow-up, the mice were sacrificed and the metastatic tumors were excised. Tumor weight was compared to evaluate the efficacy of ZOL and S. typhimurium A1-R.

Statistical analysis

Data showing comparisons among 3 or more groups were assessed using analysis of variance (ANOVA). The Kaplan-Meier method was used for bone metastasis-free survival and overall survival. Log-rank tests were used for statistical significance of the difference between the two groups. Differences were considered significant when p < 0.05. Data are expressed as mean ± SE. Statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University).

CONFLICTS OF INTEREST

There is no conflict of interest.

REFERENCES


32. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001;15:936-941.